Vazvaei-Smith Faye, Li Wenkui, Barnaby Omar S, Bhardwaj Sanjeev, Dong Juyao, Dumont Carolyne, Fernández-Metzler Carmen, Geist Brian, Hassanein Mohamed, Hays Amanda, Ilinskaya Anna, Kadar Eugene P, King Kris, Kulagina Nadia, Matta Murali K, Midde Krishna, Pan Rina, Pathania Divya, Tarnowski Thomas, Tewalt Eric, Thomas Eric, Wickremsinhe Enaksha, Xiao Deqing
Merck & Co., Inc., West Point, Pennsylvania, 19486, USA.
Novartis Biomedical Research, East Hanover, New Jersey, 07936, USA.
AAPS J. 2025 Mar 11;27(2):57. doi: 10.1208/s12248-025-01033-w.
The analysis of Non-Liquid Matrices (NLMs) can provide key information on many aspects in drug discovery and development. These include but are not limited to drug uptake and distribution, engagement and modulation, and target exposure. A thorough understanding of these aspects is fundamental to the progression of drug development. In many cases, such an understanding can only be achieved through quantitative analysis of NLMs. Such dependence can lead to bottlenecks in the drug development process-as the practices and regulations that govern bioanalysis of conventional liquid matrices typically cannot be directly applied to NLMs. This paper strives to fill this crucial gap. To this end, subject matter experts from across the industry, through the auspices of the AAPS Bioanalytical Community, have combined their collective best practices for NLM bioanalysis in this paper. Certainly, this endeavor came with challenges, the most prominent of which also serves as the impetus for this project, the lack of literature on NLM bioanalysis dealing with different types of NLM, analysis rigor, and best practices to draw from. This paper aims to serve as a comprehensive set of best practices drawn from the experiences of leading scientists across the industry-for NLM bioanalysis in drug development.
非液体基质(NLMs)的分析能够为药物研发的诸多方面提供关键信息。这些方面包括但不限于药物吸收与分布、作用与调节以及靶点暴露情况。透彻理解这些方面对于药物研发的推进至关重要。在许多情况下,只有通过对非液体基质进行定量分析才能实现这种理解。这种依赖性可能会导致药物研发过程中的瓶颈,因为用于传统液体基质生物分析的实践和法规通常不能直接应用于非液体基质。本文致力于填补这一关键空白。为此,来自整个行业的主题专家通过美国药学科学家协会(AAPS)生物分析社区的支持,在本文中汇集了他们针对非液体基质生物分析的集体最佳实践。当然,这项工作面临诸多挑战,其中最突出的挑战也是推动该项目的动力,即缺乏关于非液体基质生物分析的文献,这些文献涉及不同类型的非液体基质、分析严谨性以及可供借鉴的最佳实践。本文旨在成为一套全面的最佳实践,这些最佳实践源自整个行业顶尖科学家在药物研发中非液体基质生物分析方面的经验。